Native Mass Spectrometry and COVID-19: Uncovering Drug Binding and Oligomerization



January 29, 2021

  • Share
  • Many viruses are surrounded by lipid membranes, including SARS-CoV-2 and influenza. Both viruses contain viroporins, which are small, single pass transmembrane proteins that oligomerize to form ion channels. The influenza M2 viroporin is already a clinically approved antiviral drug target. In other coronaviruses, the E protein viroporin which is involved in growth, could be a potential target for COVID-19 vaccine and antiviral development. Although the oligomeric state of the M2 and E proteins are thought to be tetrameric and pentameric respectively, determining the oligomeric states of small transmembrane peptide complexes within membranes is challenging. Native or non-denaturing mass spectrometry (MS) data suggests a more complex picture of the oligomeric state than previously assumed, highlighting the need for novel analytical methods to understand how these important biomedical targets interact within lipid membranes. This webinar will introduce the native MS and lipid nanodisc techniques and demonstrate how this can be used to directly measure the oligomeric state of protein and peptide complexes within intact model lipid bilayers. Ongoing studies on the M2 and E protein will be discussed.

    ImmunologyMass SpectrometryProteomics and Metabolomics

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.